Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Moderna, Inc. (MRNA) vs BeOne Medicines Ltd. - Sponsored ADR (ONC)

Moderna, Inc. and BeOne Medicines Ltd. - Sponsored ADR are both Biotechnology companies. Moderna, Inc. is the larger, with a market value of $78.8B against $37.3B — 2.1× the size. Moderna, Inc. has negative trailing earnings, so its P/E is not meaningful; BeOne Medicines Ltd. - Sponsored ADR trades at 61.2×. BeOne Medicines Ltd. - Sponsored ADR grew revenue faster over the last twelve months: 34.4% against −27.6%. BeOne Medicines Ltd. - Sponsored ADR has the higher net margin (10.7% vs −141.4%) and the higher return on invested capital (60.2% vs −93.5%). Across the 18 metrics below, BeOne Medicines Ltd. - Sponsored ADR leads on 17 and Moderna, Inc. on 1.

Valuation

Metric MRNA ONC Biotechnology median
P/E n/m 61.16 7.88
P/S 35.53 6.57 11.47
P/B 11.71 7.78 2.52
Price to free cash flow n/m 30.73 21.16
EV/EBITDA n/m 34.08 0.74
EV/Sales 33.49 5.99 10.73
Earnings yield (4.02%) 1.64% (28.84%)
Free cash flow yield (1.57%) 3.25% (23.03%)

Profitability

Metric MRNA ONC Biotechnology median
Gross margin 23.38% 88.89% 65.16%
Operating margin (149.01%) 15.06% 0.00%
Net margin (141.43%) 10.70% 0.00%
Free cash flow margin (55.83%) 21.70% 0.00%
Return on equity (39.00%) 14.66% (57.72%)
Return on assets (27.43%) 8.47% (49.22%)
Return on invested capital (93.47%) 60.22% 0.00%

Growth

Metric MRNA ONC Biotechnology median
Revenue growth (TTM) (27.62%) 34.35% 5.64%
EPS growth (last fiscal year) 21.77% 141.34% —
Revenue growth, 5-year CAGR 19.34% 76.85% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric MRNA ONC Biotechnology median
Debt to equity 0.09 0.17 0.00
Current ratio 2.29 3.41 4.73
Net debt to EBITDA 1.77 (6.09) 0.96

Dividend

Metric MRNA ONC Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric MRNA ONC Biotechnology median
Market cap 78.77b 37.25b 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack